Abstract: The present invention provides an improved mode of operation of an apparatus for angioplasty or cardiac catheterization, apparatus for angioplasty and cardiac catheterization, and method of angioplasty or cardiac catheterization. The improvement and improved mode of operation includes the step of administering a therapeutically effective amount of a lipid acceptor during angioplasty or cardiac catheterization of a subject with the apparatus or component thereof. The lipid acceptor is selected from the group consisting of a large liposome comprised of phospholipids substantially free of sterol and small acceptors. The effective period of time is in the range of about less than 1 minute to about two years from the time of the angioplasty or cardiac catheterization. The improved angioplasty or cardiac catheterization apparatus includes means for administering a therapeutically effective amount of a lipid acceptor, and optional co-administration means for administering the lipid acceptor and a diagnostic agent.
Abstract: Blood cholesterol levels are correlated with production of amyloid .beta. protein (A.beta.), and are predictors of populations at risk of developing AD. Methods for lowering blood cholesterol levels can be used to decrease production of A.beta., thereby decreasing the risk of developing AD. The same methods and compositions can also be used for treating individuals diagnosed with AD. Methods include administration of compounds which increase uptake of cholesterol by the liver, such as the administration of HMG CoA reductase inhibitors, administration of compounds which block endogenous cholesterol production, such as administration of HMG CoA reductase inhibitors, administration of compositions which prevent uptake of dietary cholesterol, and administration of combinations of any of these which are effective to lower blood cholesterol levels. Methods have also been developed to predict populations at risk, based on the role of cholesterol in production of A.beta..
Abstract: A composition comprising a mixture of fatty acids such as linoleic, oleic and palmitic acids or derivatives thereof derived from secretions of mammalian mammary glands. This composition can be utilized to decrease stress, anxiety and aggressiveness in mammals.
Abstract: A mixture of 200 micrograms of the carotenoid lutein and 125 micrograms of the carotenoid zeaxanthin, along with the 10 mg of cholesterol, 100 mg olive oil, 20 mg egg yolk phospholipid, 250 micrograms alpha-tocopherol, and 0.375 ml of 0.15 M aqueous sodium chloride solution. This mixture is prepared by mixing the lipid ingredients into ethanol, evaporating the ethanol, and dispersing the lipids as an emulsion in the sodium chloride solution. The mixture is dispensed into gelatin capsules, and 2 capsules per day provide uptake of the carotenoids into the bloodstream.
Abstract: This invention provides compositions and methods for preventing and reversing the signs and symptoms of intrinsic and photo aging. The compositions include one or more pyridine-thiols and tautomers with attached metallic moieties. Administration of the compounds to aging skin and mucous membranes in topical formulations, either as the only active ingredient or in combination with other known active ingredients, prevents and reverses aging symptoms. Additional compositions for preventing and reversing aging contain one or more sulfides and oxides of these same metallic ions, either alone or in combination with other molecules known or suspected to exhibit age reversing properties. Topical formulations containing both a pyridine-thiol and tautomers with attached metallic moiety and a metallic sulfide and/or metallic oxide effectively prevent and reverse the signs and symptoms of mucocutaneous aging.
Abstract: The compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2'(1H-tetrazol-5-yl)bip henyl-4-yl-methyl]amine (valsartan) of formula ##STR1## or a salt thereof, in particular a pharmaceutically acceptable salt thereof, can be used for treating (acute and chronic) postischemic renal failure and for protecting the ischemic kidney.
Abstract: The object of the present invention is an oral drug preparation containing the .gamma.-cyclodextrin complex of diclofenac or pharmaceutically acceptable salts thereof, especially the sodium salt prepared by known methods, and by which the gastro-intestinal irritancy of diclofenac, at the same or improved bioavailability, can be considerably decreased.
Abstract: A method is provided for inhibiting or treating diseases associated with acid lipase deficiency by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, such as pravastatin.
Abstract: The invention relates to a method of altering the blood levels of LH or FSH in an individual. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
Type:
Grant
Filed:
March 29, 1996
Date of Patent:
May 23, 2000
Assignee:
Pherin Corporation
Inventors:
Clive L. Jennings-White, David L. Berliner, Nathan W. Adams
Abstract: Compositions useful to reduce cholesterol absorption. The compositions may be dosed in capsule or tablet form, or by adding either in liquid or dry powder form to foods and beverages. The compositions are an aqueous based homogeneous micellar mix which is dried to provide a mixture of finely-divided plant sterol, preferably sitostanol and lecithin. The mole ratio of the plant sterol, preferably sitostanol to lecithin, should be within the range of 1:0.1 to 1:10, preferably at least 1:2.
Abstract: Compounds and methods are provided for regulating serum glucose levels in patients by non-parenteral administration of a pharmaceutical in which a primary active ingredient is a cholerically active or other amphiphilic compound. In preferred embodiments the non-parenteral route involves transmucosal administration, and the active substance comprises a salt of a bile acid, bile acid derivative or bile acid analog. In still more preferred embodiments, the transmucosal administration comprises administration to a nasal membrane.
Abstract: An agent for the prophylaxis or treatment of muscle tissue degeneration, containing, as an active ingredient, a quinoline compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt. The prophylactic or therapeutic agent of muscle tissue degeneration of the present invention contains a quinoline compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and shows remarkable inhibitory or improving action on degeneration of the muscle tissues such as necrosis, fibrosis, calcification and the like. The agent is specifically useful for the prophylaxis and treatment of cardiomyopathy, muscular dystrophy, pulmonary fibrosis and the like.
Abstract: The present invent is directed to a pharmaceutical composition comprising a pharmaceutically effective amount of cyclosporin in association with a pharmaceutical carrier, said carrier comprising a drug solubilizing effective amount of a fatty acid having 6-22 carbon atoms and a non-ionic surfactant.
Abstract: [Object] : To provide a pharmaceutical preparation for treating or preventing hyperlipemia which lowers cholesterols and neutral fats in blood and has a property to improve lipoprotein metabolism.[Construction] : A pharmaceutical preparation for treating or preventing hyperlipemia comprising taurine and .gamma.-oryzanol as effective components.
Abstract: A method is provided for inhibiting onset of or treating phytosterolemia by administering to a patient an MTP inhibitor, alone or optionally, in combination with another cholesterol lowering drug, such as pravastatin.
Abstract: A composition comprising a mixture of fatty acids such as oleic, palmitic and linoleic acids and derivatives thereof which are used for enhancing weight gain in a mammal. Methods to enhance weight gain using the fatty acid compositions are also described.
Abstract: The invention relates to methods of utilizing descarboethoxyloratadine ("DCL") for the treatment of dermatitis. The invention also encompasses the topical administration of descarboethoxyloratadine using various dosage forms for the treatment of dermatitis.
Abstract: The use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent, is disclosed.
Type:
Grant
Filed:
September 16, 1996
Date of Patent:
April 4, 2000
Assignee:
Children's Medical Center Corporation
Inventors:
Charles B. Berde, Robert S. Langer, Joanne Curley, Jenny Castillo
Abstract: A medicament for preventive and therapeutic treatment of obesity and a disease with abnormal lipid metabolism which comprises as an active ingredient a compound selected from the group consisting of 24-alkylcholestan-3-ones and 24-alkylcholesten-3-ones such as 24-alkylcholestan-3-ones, 24-alkylcholestmonoen-3-ones, 24-alkylcholestdien-3-ones, 24-alkylcholesttrien-3-ones and 24-alkylcholesttetraen-3-ones.
Type:
Grant
Filed:
November 5, 1998
Date of Patent:
April 4, 2000
Assignee:
The Institute of Physical and Chemical Research, and Kunio Suzuki
Abstract: This invention relates to the use of a product that contains in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen for its sequential, oral administration, in which each individual dosage unit that contains the competitive progesterone antagonist contains the latter in a non-abortion-inducing amount for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri.